Loading...
Docoh

Selecta Biosciences (SELB)

News

From Benzinga Pro
Expert Ratings for Selecta Biosciences
21 Jun 22
Analyst Ratings
Over the past 3 months, 4 analysts have published their opinion on Selecta Biosciences (NASDAQ:SELB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
HC Wainwright & Co. Maintains Buy on Selecta Biosciences, Lowers Price Target to $4
21 Jun 22
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $6 to $4.
63 Biggest Movers From Yesterday
17 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
Needham Maintains Buy on Selecta Biosciences, Lowers Price Target to $5
14 Jun 22
News, Price Target, Analyst Ratings
Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $6 to $5.
Selecta Biosciences Announces Partnership Advancements And Clinical Trial Updates; Selecta To Receive A $2M Payment From Sarepta Plus Up To $10M In Potential Achievements
13 Jun 22
Biotech, News, Contracts, General
-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta extending their
91 Biggest Movers From Friday
13 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
44 Stocks Moving In Friday's Mid-Day Session
10 Jun 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
SVB Leerink Sees Over 600% Upside For This Penny Biotech Stock
6 Jun 22
Analyst Color, Biotech, News, Penny Stocks, Health Care, Price Target, Initiation, Analyst Ratings, Movers, Trading Ideas, General
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022
6 Jun 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
SVB Leerink Initiates Coverage On Selecta Biosciences with Outperform Rating, Announces Price Target of $7
6 Jun 22
News, Price Target, Initiation, Analyst Ratings
SVB Leerink analyst Joseph Schwartz initiates coverage on Selecta Biosciences (NASDAQ:SELB) with a Outperform rating and announces Price Target of $7.
24 Stocks Moving in Thursday's Pre-Market Session
2 Jun 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an animal study in Soft Tissue Sarcoma (STS).
Executives Buy Around $1.5M Of 4 Penny Stocks
12 May 22
Long Ideas, News, Penny Stocks, Small Cap, Insider Trades, Markets, Trading Ideas
US stock futures traded lower this morning on Thursday ahead of the producer price index. Investors, meanwhile, focused on some notable insider trades.
Needham Maintains Buy Rating for Selecta Biosciences: Here's What You Need To Know
6 May 22
Analyst Ratings
Needham has decided to maintain its Buy rating of Selecta Biosciences (NASDAQ:SELB) and lower its price target from $7.00 to $6.00. Shares of Selecta Biosciences are trading up 2.84% over the last 24 hours, at $0.83 per share.
Needham Maintains Buy on Selecta Biosciences, Lowers Price Target to $6
6 May 22
News, Price Target, Analyst Ratings
Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $7 to $6.
Recap: Selecta Biosciences Q1 Earnings
5 May 22
Earnings
Selecta Biosciences (NASDAQ:SELB) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
5 May 22
Biotech, Earnings, News, Penny Stocks, Health Care, Contracts, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Selecta Biosciences Q1 EPS $0.08 Up From $(0.22) YoY
5 May 22
Earnings, News
Selecta Biosciences (NASDAQ:SELB) reported quarterly earnings of $0.08 per share. This is a 136.36 percent increase over losses of $(0.22) per share from the same period last year.
Earnings Scheduled For May 5, 2022
5 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Earnings Outlook For Selecta Biosciences
4 May 22
Earnings
Selecta Biosciences (NASDAQ:SELB) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Selecta Biosciences will report an earnings per share (EPS) of $-0.11.
Stocks That Hit 52-Week Lows On Wednesday
4 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's trading, 435 companies set new 52-week lows.

Press releases

From Benzinga Pro
Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates
13 Jun 22
Health Care, Analyst Ratings, Press Releases
-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta extending their
Thinking about buying stock in Applied UV, Nio, Wejo Group, Helius Medical Technologies, or Selecta Biosciences?
9 Jun 22
Opinion, Press Releases
NEW YORK, June 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUVI, NIO, WEJO, HSDT, and SELB.
Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
17 May 22
News, Press Releases
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for
Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
5 May 22
Earnings, Press Releases
– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – – Completed underwritten
Selecta Biosciences Announces Six Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2 May 22
News, Press Releases
WATERTOWN, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
28 Apr 22
News, Press Releases
WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies that
Selecta Biosciences Announces $38.7 Million Underwritten Offering
6 Apr 22
Press Releases
WATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB) ("Selecta" or the "Company"), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune